drugset
drugset / Trial / NCT03259542

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

NCT03259542 ↗

Phase 1 Completed 33 enrolled Corcept Therapeutics
NaSingle-groupOpen-labelOther

Summary

This is a Phase 1, single-center, fixed-sequence, open label, drug-drug interaction study of the effect of multiple daily doses of oral itraconazole 200 mg, a strong inhibitor of CYP3A, given with mifepristone 900 mg QD, in healthy male subjects, where all drug administrations are given after a meal.

Timeline

Start
2017-08-09
Primary completion
2017-12-11
Completion
2017-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject Mifepristone Small molecule 900 mg Oral

Indications

No indication recorded.